SCHEMBL290791

SCHEMBL290791

O=C1CCC(=O)N1Cc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.70
ELANE P08246 2/20 0.64
F2 P00734 1/20 0.64
PLG P00747 1/20 0.64
CTSG P08311 1/20 0.64
CMA1 P23946 1/20 0.64
CTRC Q99895 1/20 0.64
GSK3A P49840 4/20 0.60
GSK3B P49841 4/20 0.60
MGLL Q99685 1/20 0.59
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ALDH1A1 P00352 3/20 0.53
MAPT P10636 2/20 0.53
APAF1 O14727 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL25171118 0.94 POLB (0.64) POLBELANEF2PLGCTSG
SCHEMBL40679 0.91 POLB (0.61) POLBELANEF2PLGCTSG
SCHEMBL5769842 0.88 MGLL (0.65) POLBELANEF2PLGCTSG
SCHEMBL31114554 0.86 POLB (0.60) POLBELANEF2PLGCTSG
SCHEMBL10688767 0.83 POLB (1.00) POLBMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL29880432 0.83 POLB (1.00) POLBMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL17725335 0.83 POLB (0.57) POLBELANEF2PLGCTSG
SCHEMBL17712991 0.83 POLB (0.57) POLBELANEF2PLGCTSG
SCHEMBL10559302 0.81 GSK3A (0.70) POLBELANEF2PLGCTSG
SCHEMBL11620172 0.81 ELANE (0.57) POLBELANEF2PLGCTSG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025121320-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR POLYCYSTIC KIDNEY DISEASE 国立大学法人山口大学 2025-06-12 WO claimed
CN-119977886-A Pentazocine gluconate benzoate and preparation method and application thereof 安徽益普克医药科技发展有限公司 2025-05-13 CN claimed
CN-118851946-A Method for preparing long fatty chain diacid derivative and application thereof 广东东阳光药业股份有限公司 2024-10-29 CN claimed
CN-113264866-B Non-fluorescent organic small molecular compound, preparation method of pentamethyl cyanine dye and application of pentamethyl cyanine dye 南京大学 2023-04-07 CN claimed
CN-113264866-A Non-fluorescent organic small molecular compound, preparation method of pentamethyl cyanine dye and application of pentamethyl cyanine dye 南京大学 2021-08-17 CN claimed
EP-2859069-B1 METHOD AND APPARATUS FOR TREATING PETROLEUM EQUIPMENT FERRARA MARCELLO (IT) 2020-10-14 EP claimed
US-9328300-B2 Method, apparatus and chemical products for treating petroleum equipment FERRARA MARCELLO (IT) 2016-05-03 US claimed
EP-2859069-A1 METHOD AND APPARATUS FOR TREATING PETROLEUM EQUIPMENT Ferrara, Marcello (IT) 2015-04-15 EP claimed
WO-2013156228-A1 METHOD AND APPARATUS FOR TREATING PETROLEUM EQUIPMENT FERRARA MARCELLO (IT) 2013-10-24 WO claimed
US-20130270157-A1 METHOD, APPARATUS AND CHEMICAL PRODUCTS FOR TREATING PETROLEUM EQUIPMENT FERRARA MARCELLO (IT) 2013-10-17 US claimed
WO-2009149054-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2009-12-10 WO claimed
US-20040127707-A1 PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders ALTANA PHARMA AG (DE) 2004-07-01 US claimed
EP-1385848-A2 PHTALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS ALTANA Pharma AG (DE) 2004-02-04 EP claimed
EP-0971901-B1 PHTHALAZINONES ALTANA PHARMA AG (DE) 2003-02-26 EP claimed
WO-2002085906-A2 PHTHALAZINONES DERIVATIVES USEFUL AS PDE4/7 INHIBITORS ALTANA PHARMA AG (DE) 2002-10-31 WO claimed
US-6103718-A Phthalazinones BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2000-08-15 US claimed
EP-0971901-A1 PHTHALAZINONES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2000-01-19 EP claimed
WO-1998031674-A1 PHTHALAZINONES BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1998-07-23 WO claimed
WO-1995020637-A2 HYDROCARBON OIL-AQUEOUS FUEL AND ADDITIVE COMPOSITIONS MEG S.N.C. DI SCOPELLITI SOFIA & C. (IT) 1995-08-03 WO claimed
EP-0310854-A1 Process for the manufacture of 3-amino-1-benzyl-pyrrolidines BAYER AG (DE) 1989-04-12 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127707-A1 PDE4/7 inhibitors useful in treatment of airway disorders, autoimmune system disorders, skin disorders, arthritis, nerve system disorders PDE4A, PDE4B, PDE7B POLB 972/4885ELANE 1636/4885F2 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.